Total
0
Shares
Cellmid (ASX:CDY) midkine patents granted in the U.S. and Europe
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cellmid (CDY) has received notice of allowance for an improved antibody patent from the United States Patent and Trademark Office
  • Key U.S. and European patents have now been granted for its midkine antibodies
  • These patents secure protection for midkine antibodies to treat cancer, inflammatory diseases and auto-immune disorders
  • Cellmid is currently up a steady 7.14 per cent with shares trading for 22.5 cents apiece

Cellmid (CDY) has received notice of allowance for the improved antibody patent from the United States Patent and Trademark Office (USPTO).

Additionally, following a Notification of Intention to Grant from the European Patent Office (EPO) for the Improved midkine antibody patent, the EPO has now issued a decision to grant.

The simultaneous granting of these patents in the U.S. and key European areas represents a major milestone in the midkine therapeutic program.

The humanised therapeutic antibody covered by both the patents is one of the lead drugs in the midkine program and adds significant commercial value to the comprehensive intellectual property portfolio around midkine.

This newly granted midkine antibody patents and allied patent families underpin Cellmid's dominant intellectual property position over the use of midkine therapeutic antibodies for the treatment of diseases arising from cancer and chronic inflammation.

Midkine is a growth factor that is highly expressed during embryonic development and it modulates many important biological interactions such as cell growth, cell migration and cellular adherence.

These functions are relevant to cancer, inflammation, autoimmunity, wound healing, and. nerve growth and repair.

Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of disorders.

It's often evident very early in disease onset even before any apparent physical symptoms and it's only evident in a disease context and targeting midkine is not expected to harm normal healthy tissues.

Cellmid's total midkine patent portfolio currently comprises of 67 patents and applications in 12 patent families.

Cellmid is currently up a steady 7.14 per cent with shares trading for 22.5 cents apiece at 11:40 am AEDT.

CDY by the numbers
More From The Market Herald
Digital Wine Ventures (ASX:DW8) - CEO, Dean Taylor - The Market Herald

" Digital Wine Ventures (ASX:DW8) sees 350pc spike in April orders

Digital Wine Ventures (DW8) processed 9512 WINEDEPOT orders over April, which marks a 350 per cent increase on the prior corresponding period.
Vection Technologies (ASX:VR1) lands $300K contract with MYR

" PointsBet (ASX:PBH) takes a gamble on Premier Turf Club

PointsBet’s (PBH) subsidiary, PointsBet USA, has entered a binding agreement to acquire Premier Turf Club for US$2.9 million (roughly A$3.7 million).
Briscoe Group (ASX:BGP) - Managing Director Rod Duke - The Market Herald

" Briscoe Group’s (ASX:BGP) Q1 sales up 78pc

Briscoe Group (BGP) has updated the market on its first quarter sales to May 2, 2021.
Eclipx (ASX:ECX) - Chair, Gail Pemberton - The Market Herald

" Eclipx (ASX:ECX) soars on strong half-year report and new Chair

Car leasing company Eclipx (ECX) has spiked on the ASX today after posting an increase in profit and income over the first half